



February 25, 2025

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-6374-9702

Digital Therapeutics Development for Chronic Cough Treatment

KYORIN Pharmaceutical Co., Ltd. announced today that KYORIN has entered into a development and commercialization agreement with Hyfe Inc. (Wilmington DE, CEO: Tamsin Chislett) for digital therapeutics (DTx) for chronic cough and are currently developing the DTx in Japan.

The DTx for chronic cough under development is based on the principles of BCST (Behavioral Cough Suppression Therapy), which is a non-pharmacological treatment method used to reduce chronic cough by facilitating changes in patient behavior, and utilizes cough monitoring technology powered by Hyfe's AI. KYORIN will develop DTx tailored for the Japanese market using expertise in respiratory diseases. Based on this agreement, KYORIN will pay Hyfe milestone payments tied to the progress of developing and commercializing the DTx product, and royalties based on net sales following its launch.

KYORIN aims to create high-value new drugs that meet medical needs under its long-term vision "Vision 110", and contribute to clinical development by providing new treatment options for chronic cough.

The impact on business performance for the fiscal year ending March 2025 is to be negligible.

[Reference]

About Hyfe Inc.

Hyfe, Inc. is the global leader in AI-powered cough-monitoring technology. The company's patented machine-learning software enables passive, long-term monitoring of cough frequency, revealing novel health insights. Hyfe delivers cough-monitoring solutions that empower pharma and academic researchers to advance clinical trials, enable healthcare providers to optimize patient care, and power digital therapeutics to transform the management of respiratory illness, including chronic cough. Hyfe's technology has been used in 50+ research studies, and its long-term partners include global pharma companies and leading academic institutions. More information is available at hyfe.com.

About BCST (Behavioral Cough Suppression Therapy)

BCST, a non-pharmacological treatment method used to reduce chronic cough by facilitating changes in patient behavior, improves cough outcomes in up to 88% of patients¹. In addition, BCST has been shown to reduce cough in people with refractory chronic cough and unexplained chronic cough by 41%, significantly higher than any drug available on the market². However, BCST is only offered in-person by under 200 speech language pathologists in the U.S. and very few in Japan. This DTx for chronic cough treatment aims to provide personalized information through patients' smartphones by combining BCST with AI-powered cough monitoring technology. By development of this DTx, we aim to offer a new treatment option and contribute to patients suffering from chronic cough.

(1) Vertigan A, et al., An update on speech pathology management of chronic refractory cough. *J Allergy Clin Immunol Pract.* 2019;7(6):1756-1761.

(2) Chamberlain Mitchell SA, et al., Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. *Thorax.* 2017;72(2):129-136.